290 related articles for article (PubMed ID: 29525892)
1. When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.
Bollam SR; Berens ME; Dhruv HD
Curr Neurol Neurosci Rep; 2018 Mar; 18(4):15. PubMed ID: 29525892
[TBL] [Abstract][Full Text] [Related]
2. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
[TBL] [Abstract][Full Text] [Related]
3. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
[TBL] [Abstract][Full Text] [Related]
4. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
[TBL] [Abstract][Full Text] [Related]
5. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
7. Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.
Wang X; Li X; Xu F; Zhang Y; Liu H; Tao Y
Mol Neurobiol; 2016 May; 53(4):2726-32. PubMed ID: 26351078
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.
You H; Wu Y; Chang K; Shi X; Chen XD; Yan W; Li R
CNS Neurosci Ther; 2017 Oct; 23(10):790-797. PubMed ID: 28868656
[TBL] [Abstract][Full Text] [Related]
9. Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
Masui K; Komori T; Kato Y; Masutomi K; Ichimura K; Ogasawara S; Kaneko MK; Oki H; Suzuki H; Nitta M; Maruyama T; Muragaki Y; Kawamata T; Sawada T; Shibata N
Biomed Res Int; 2018; 2018():7945845. PubMed ID: 29693015
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
11. Rapid progression of an IDH-wild type histological low-grade glioma harbouring TERT promoter mutation and diffuse CD34 expression: a case report.
Wang H; Tan C; Xu T; Li W
Folia Neuropathol; 2021; 59(1):104-111. PubMed ID: 33969682
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo.
Miki S; Koga T; Mckinney AM; Parisian AD; Tadokoro T; Vadla R; Marsala M; Hevner RF; Costello JF; Furnari F
Neuro Oncol; 2022 Dec; 24(12):2063-2075. PubMed ID: 35325218
[TBL] [Abstract][Full Text] [Related]
13. Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas.
Fan X; Wang Y; Liu Y; Liu X; Zhang C; Wang L; Li S; Ma J; Jiang T
J Neurooncol; 2016 Jul; 128(3):455-62. PubMed ID: 27230769
[TBL] [Abstract][Full Text] [Related]
14. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
[TBL] [Abstract][Full Text] [Related]
15. Human TERT promoter mutations as a prognostic biomarker in glioma.
Powter B; Jeffreys SA; Sareen H; Cooper A; Brungs D; Po J; Roberts T; Koh ES; Scott KF; Sajinovic M; Vessey JY; de Souza P; Becker TM
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1007-1017. PubMed ID: 33547950
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.
Heidenreich B; Rachakonda PS; Hosen I; Volz F; Hemminki K; Weyerbrock A; Kumar R
Oncotarget; 2015 Apr; 6(12):10617-33. PubMed ID: 25797251
[TBL] [Abstract][Full Text] [Related]
17. TERT mutation in glioma: Frequency, prognosis and risk.
Yuan Y; Qi C; Maling G; Xiang W; Yanhui L; Ruofei L; Yunhe M; Jiewen L; Qing M
J Clin Neurosci; 2016 Apr; 26():57-62. PubMed ID: 26765760
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Killela PJ; Reitman ZJ; Jiao Y; Bettegowda C; Agrawal N; Diaz LA; Friedman AH; Friedman H; Gallia GL; Giovanella BC; Grollman AP; He TC; He Y; Hruban RH; Jallo GI; Mandahl N; Meeker AK; Mertens F; Netto GJ; Rasheed BA; Riggins GJ; Rosenquist TA; Schiffman M; Shih IeM; Theodorescu D; Torbenson MS; Velculescu VE; Wang TL; Wentzensen N; Wood LD; Zhang M; McLendon RE; Bigner DD; Kinzler KW; Vogelstein B; Papadopoulos N; Yan H
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6021-6. PubMed ID: 23530248
[TBL] [Abstract][Full Text] [Related]
20. The Sensitive Detection of Telomerase Reverse Transcriptase Promoter Mutation by Amplification Refractory Mutation System-PCR.
Liu J; Zhao Z; Sun M; Chen K; Yuan W; Jiang G
Genet Test Mol Biomarkers; 2016 Feb; 20(2):90-3. PubMed ID: 26741813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
